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different cytokines such as IL-1  , IL-1  , IL-6, IL-8, (KC) 
and MCP-1, which in turn alter the expression and secre-
tion pattern of adipokines and cytokines and stimulate the 
release of FAs by elevating basal lipolysis. All of these 
changes contribute to the development of detrimental 
complications of obesity such as insulin resistance and dia-
betes mellitus ( 2, 3 ). 
 Lipolysis is physiologically stimulated by the catecholamine 
hormones noradrenaline and adrenaline through activation 
of protein kinase A (PKA). Further downstream, PKA acti-
vates hormone-sensitive lipase (HSL), perilipin 1, and adi-
pose triglyceride lipase (ATGL), resulting in triglyceride 
breakdown ( 4 ). Besides this well-established regulation of 
lipolysis by catecholamines, tumor necrosis factor   (TNF  ) 
is another potent inducer of lipolysis in adipocytes ( 5 ). TNF  -
mediated lipolysis involves activation of the p44/42 MAP ki-
nases (ERK1/2) leading to downregulation of the lipid 
droplet coating protein perilipin ( 6 ). 
 Fas (FasR, CD95, apo-1) is a type I transmembrane pro-
tein that belongs to the tumor necrosis factor (TNF)/
nerve growth factor (NGF) receptor superfamily ( 7 ) and 
is activated by Fas ligand (FasL, CD95L), a type II mem-
brane protein ( 8 ). Fas was fi rst described in 1989 as a surface 
molecule on lymphocytes that can trigger cell death ( 9 ). 
In the adult mouse, Fas and FasL are expressed in several 
tissues including WAT ( 10, 11 ). Upon binding of FasL, 
preformed trimeric Fas complexes undergo a conforma-
tional change that results in the formation of a death-
inducing signaling complex and activation of downstream 
pathways leading to apoptosis ( 9, 12 ). However, in addition 
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 White adipose tissue (WAT) has major metabolic and 
endocrine functions mediated by secretion of different 
adipokines and fat-derived metabolites such as NEFAs. 
These molecules regulate food intake, energy expendi-
ture, and glucose homeostasis ( 1, 2 ). In obesity, excess 
WAT accumulation is accompanied by local infi ltration 
of macrophages and other infl ammatory cells secreting 
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Invitrogen) and electro-transferred onto nitrocellulose mem-
branes (0.2   m; BioRad, Reinach, Switzerland). Protein content 
on membranes was checked by Ponceau S staining. Blots were 
blocked in tris-buffered saline containing 0.1% Tween (TBS-T) 
supplemented with 5% nonfat dry milk. Primary antibody was 
applied in the same buffer in a dilution of 1:1,000, secondary 
antibody in a dilution of 1:5,000. Primary antibodies were pur-
chased either from Cell Signaling Technology [phospho-p44/42 
and total MAPKs, phospho-(Ser/Thr) PKA substrate, phospho-
Ser 563, and total HSL, ATGL (MBL International; Woburn, MA); 
perilipin A, Millipore Actin, Fas (CD95)], Vala Sciences (phos-
pho-Perilipin Ser 522), or Santa Cruz Biotechnology (PPAR  2 , 
C/EBP  , pCaMKII  (Thr 286). Signal was generated based on 
chemiluminescence and detected with the Fuji LAS-3000 image 
reader. 
 Measurement of lipolysis 
 Cells were incubated in DMEM without FCS and treated with 
2 ng/ml FasL or 1 µM isoproterenol in the presence or absence 
of 50   M of the MEK inhibitor U0126 (Sigma), of 50   M of the 
intracellular calcium chelator BAPTA/AM (Calbiochem), or of 
50   M of CaMKII inhibitor KN62 (Sigma), as indicated. Inhibi-
tors or BAPTA/AM were added to the cells at the same time as 
FasL. Thereafter, cells were washed in PBS, and NEFA and glyc-
erol were collected in Krebs-Ringer-HEPES buffer supplemented 
with 0.1% FA-free BSA for 1 h. NEFAs in the supernatant were 
measured with the NEFA kit from Wako (Neuss, Germany), and 
glycerol with the free glycerol reagent from Sigma. Fractional 
re-esterifi cation was calculated as previously described ( 20 ). 
 Data analysis 
 Data are presented as means ± SEM and were analyzed by a 
one-sample  t -test or ANOVA with a Newman-Keuls multiple com-
parison test. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 RESULTS 
 Fas activation induces lipolysis in 3T3-L1 adipocytes 
 The Fas receptor (CD95) is expressed in 3T3-L1 preadi-
pocytes and decreases during adipocyte differentiation, 
but is still clearly expressed in mature adipocytes  ( Fig. 1 ). 
Expression levels of the adipocyte-specifi c proteins PPAR  2 , 
C/EBP  , and perilipin refl ect the respective stages of dif-
ferentiation. Treatment of differentiated 3T3-L1 adipo-
cytes with 2 ng/ml FasL for 12 h signifi cantly increased 
[AQ5]
to this well-established role of Fas in apoptosis, Fas activa-
tion contributes to nonapoptotic signaling pathways, 
including cell proliferation ( 9, 13 ) and the induction of 
infl ammatory responses in different cell types ( 14–18 ). 
Moreover, we have recently reported that Fas is increasingly 
expressed in WAT of obese subjects and that Fas-defi cient 
and adipocyte-specifi c Fas knockout mice are partly pro-
tected from high-fat diet-induced insulin resistance ( 11, 19 ), 
implicating a role for Fas in the pathogenesis of obesity-
associated insulin resistance. Although the underlying 
mechanism remains incompletely understood, livers of 
adipocyte-specifi c Fas knockout mice had lower levels of 
total ceramides, which are potentially metabolized from 
NEFA delivered to the liver from adipose tissue. Thus, in 
the present study, we hypothesized that in adipocytes, Fas 
activation can, independently of its pro-apoptotic effects, 
directly induce the hydrolysis of triglycerides (i.e., increase 
basal lipolysis), and set-up to investigate the intracellular 
signaling pathway(s) involved. 
 MATERIALS AND METHODS 
 Cell culture 
 3T3-L1 adipocytes were cultured in DMEM (Invitrogen; Basel, 
Switzerland) containing 25 mM glucose (high glucose), supple-
mented with 10% fetal calf serum (FCS; Socochim SA, Lausanne) 
and antibiotics (Invitrogen). Forty-eight hours after reaching con-
fl uence (day 0, D0), cells were treated with a mixture of 500   M 
methylisobutylxanthine, 1   M dexamethasone, 1.7   M insulin (all 
from Sigma; Buchs, Switzerland), and 1   M rosiglitazone (Alexis 
Biochemicals) to induce differentiation. Two days later (D2) the 
medium was changed to high-glucose culture medium containing 
insulin (0.5   M). Another 2 days later (D4), the medium was re-
placed by culture medium without insulin. The culture medium was 
replaced every other day and changed to culture medium contain-
ing 5.5 mM glucose (low glucose) after 4 days (D8). Cells were kept 
at least 2 days on low glucose before experiments were performed. 
Membrane-bound Fas ligand (Upstate; Lake Placid, NY) was added 
to low-glucose serum-free medium as indicated. For pretreatment 
experiments with rosiglitazone (Enzo Life Science; Lausen, Switzer-
land), mature adipocytes were incubated for 48 h with 5   M of the 
compound in low-glucose medium. Thereafter, FasL, together with 
rosiglitazone, was applied for another 6 h or 12 h. 
 For siRNA-mediated ERK1/2 knock down, mature 3T3-L1 
adipocyte cells were treated with siRNA (target sequences for 
ERK1/2: 5 ′ ACAAGCGCATCACAGTAGA 3 ′ , 5 ′ GAACCCTAA-
GAGAGATAAA 3 ′ ; scrambled sequences for ERK1/2: 5 ′ GCAAC-
CGAACGGAAACATT 3 ′ , 5 ′ GAACAAAGTAACGGTAACA 3 ′ ) 
in a transfection mixture containing Lipofectamin 2000 (Invitro-
gen) in culture medium (low-glucose, without FCS, without p /s) 
according to the manufacturer’s instructions. 
 Western blotting 
 Adipocytes were lysed in ice-cold lysis buffer containing 150 mM 
NaCl, 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 1% NP-40, 0.25% 
sodium deoxycholate, 1 mM sodium vanadate, 1 mM NaF, 10 mM 
sodium   -glycerophosphate, 100 nM okadaic acid, 0.2 mM 
PMSF, and a 1:1,000 dilution of protease inhibitor cocktail 
(Sigma). Protein concentration was determined using a BCA 
assay (Pierce; Rockford, IL). Equal amounts of protein were 
resolved by lithium dodecyl sulfate PAGE (4–12% gel; NuPAGE, 
[AQ2]
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 Fig.  1. The Fas receptor is expressed in 3T3-L1 cells. Lysates of 
3T3-L1 preadipocytes (PreAC), differentiating (day (D) 1, 2, 4, and 
6) and mature adipocytes (AC) were resolved by LDS-PAGE and 
immunoblotted with an antibody against the Fas receptor, PPAR  2 , 
C/EBP  , and perilipin. 
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receptor superfamily, we postulated that FasL-induced 
lipolysis is mediated via ERK1/2 activation. Incubation of 
mature 3T3-L1 adipocytes with 2 ng/ml FasL increased 
phosphorylation of ERK1/2 signifi cantly after 6 h and 12 h, 
whereas total protein concentration of ERK1/2 was not 
affected  ( Fig. 4A ). To exclude the possibility that the effects 
of FasL treatment were due to a FasL-mediated increase in 
TNF  secretion and, thus, to a paracrine regulatory loop 
mediated by this cytokine, TNF  concentration was deter-
mined in the supernatant. As depicted (see supplemen-
tary  Fig. V ), incubation with 2 ng/ml FasL for 12 h did not 
lead to increased TNF  secretion to the medium. We 
therefore concluded that Fas-mediated ERK1/2 activation 
was independent of TNF  . 
 To assess whether Fas-induced lipolysis is dependent on 
ERK1/2 activation, we incubated 3T3-L1 cells in the pres-
ence or absence of the MEK1/2 inhibitor U0126. Inhibi-
tion of the MAP kinase pathway with U0126 (50   M) 
completely blocked Fas-induced ERK1/2 phosphorylation 
and lipolysis ( Fig. 4B ). To further strengthen a role of the 
p44/42 MAP kinase pathway in Fas-mediated lipolysis, 3T3-L1 
adipocytes were treated with targeted or scrambled siRNA 
against ERK1/2, respectively. Compared with scrambled 
siRNA control, siRNA targeted toward ERK1/2 decreased 
ERK1/2 protein by about 50%, an effect that was associ-
ated with a signifi cant blunting of FasL-stimulated lipolysis 
( Fig. 4C ). Thus, Fas-stimulated lipolysis is dependent on 
ERK1/2 activation. 
 To further corroborate a Fas-ERK1/2-lipolysis pathway 
in adipocytes, we tested whether PPAR  agonists such as 
thiazolidinediones (TZDs), which were demonstrated to in-
hibit whole-body lipolysis in patients with type 2 diabetes ( 22 ), 
could inhibit Fas-induced lipolysis and if so, whether activa-
tion of ERK1/2 was also diminished. As shown in  Fig. 4D , 
FasL-stimulated ERK1/2 phosphorylation was reduced in 
the presence of rosiglitazone without affecting total 
ERK1/2 protein content. Correspondingly, rosiglitazone 
also reduced FasL-mediated lipolysis ( Fig. 4D ). 
 Fas-mediated lipolysis is CaMKII dependent 
 CaMKII was previously shown to mediate magnolol-trig-
gered lipolysis in sterol ester-loaded 3T3-L1 preadipocytes 
in an ERK1/2-dependent fashion ( 23 ). We therefore 
lipolysis  ( Fig. 2 ), consistent with our earlier observation 
( 8 ), and without affecting their viability as assessed by 
TUNEL assay (see supplementary  Fig. I ) and MTT deter-
mination ( 11 ). Fractional reesterifi cation did not decrease 
upon FasL incubation (basal: 68.0 ± 2.6%; 6 h FasL: 64.0 ± 
6.0%; 12 h FasL: 63.6 ± 5.5%;  P = 0.8). Such data suggest 
that Fas activation increases lipolysis by increased triglycer-
ide hydrolysis rather than by decreased reesterifi cation. 
Shorter incubation periods with FasL (  6 h) and lower 
concentrations of FasL did not increase lipolysis to a sig-
nifi cant degree (see supplementary  Fig. II ). Moreover, 
blunted Fas-stimulated lipolysis in Fas-depleted 3T3-L1 
adipocytes suggests that membrane-bound FasL signals via 
the Fas receptor (see supplementary  Fig. III ). 
 Fas activation increases phosphorylation of HSL 
 Beta adrenergic receptor agonists such as catecholamines 
stimulate lipolysis via adenylate cyclase-dependent activa-
tion of PKA and consecutive activation of HSL, perilipin 1, 
and ATGL. Inhibiting such effect, insulin activates phos-
phodiesterase 3, which converts cAMP to 5 ′ -AMP, thereby 
diminishing cAMP-mediated PKA activity, which results in 
inhibition of lipolysis. To examine whether Fas-mediated 
lipolysis comprises activation of PKA, phosphorylation of 
PKA substrates was determined in 3T3-L1 adipocytes. As 
expected, the   1,2 receptor agonist isoproterenol increased 
phosphorylation of PKA substrates signifi cantly. In con-
trast, treatment with FasL had no effect on the abundance 
of phosphorylated PKA substrates  ( Fig. 3A ). However, 
even though not detected by the PKA substrate antibody, 
incubation of 3T3-L1 adipocytes with FasL for 6 h and 12 h 
signifi cantly increased phosphorylation of HSL at Ser563 
( Fig. 3B ), whereas it had no effect on total HSL protein 
levels (see supplementary  Fig. IV ) and phosphorylation 
of perilipin ( Fig. 3B ). In addition, ATGL protein levels 
were slightly but not signifi cantly upregulated upon Fas 
incubation ( Fig. 3C ). Thus, Fas-mediated lipolysis may 
depend on activation of HSL and/or ATGL. 
 Fas-mediated lipolysis is ERK dependent 
 An alternative signaling pathway to activate lipolysis in 
adipocytes involves the p44/42 MAP kinases (ERK1/2), as 
was shown for TNF  ( 21 ). Because Fas belongs to the TNF 
[AQ6]
 Fig.  2. Fas stimulation induces lipolysis in 3T3-L1 adipocytes. Fully differentiated 3T3-L1 adipocytes were 
treated with FasL (2 ng/ml) for the indicated time periods. NEFA (A) and glycerol (B) concentrations were 
determined in the supernatant collected for 1 h as described in Materials and Methods. Results represent the 
means ± SEM of six independent experiments. * P < 0.05. 
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the latter, the developing calcium/calmodulin complex 
may activate CaMKII, leading to intramolecular autophos-
phorylation at several sites, including Thr286, Thr305, 
and Thr306 ( 25 ). As depicted in  Fig. 5B , incubation of ma-
ture 3T3-L1 adipocytes with 2 ng/ml FasL increased phos-
phorylation of CaMKII at Thr286 signifi cantly after 6 h 
and 12 h. Moreover, pretreatment with the CaMKII inhibi-
tor KN62 reduced FasL-mediated ERK1/2 activation as 
postulated that FasL-induced lipolysis may be dependent on 
intracellular changes in calcium levels, because it is well 
accepted that Fas activation can increase intracellular cal-
cium levels ( 24 ). Indeed, preincubation of 3T3-L1 adipo-
cytes with the intracellular calcium chelator BAPTA/AM 
prevented both FasL-induced ERK activation and lipolysis 
 ( Fig. 5A ), suggesting that both effects of Fas activation are 
dependent on an intracellular calcium rise. In response to 
 Fig.  3. Fas activation increases phosphorylation of HSL. Fully differentiated 3T3-L1 adipocytes were 
treated with FasL (2 ng/ml) for the indicated time periods or isoproterenol (1 µM) for 30 min. Lysates were 
resolved by LDS-PAGE and immunoblotted with phospho-(Ser/Thr) PKA substrate (A), phospho-HSL 
(Ser563), and phospho-perilipin (B) or ATGL (C) antibodies. Shown are representative blots and densitom-
etry analyses of four to eight independent experiments. * P < 0.05, ** P < 0.01. 
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 Fig.  4. Fas-mediated lipolysis is ERK dependent. A: Fully differentiated 3T3-L1 adipocytes were treated 
with FasL (2 ng/ml) as indicated. Lysates were resolved by LDS-PAGE and immunoblotted with phosphory-
lated (Thr202/Tyr204) and total ERK1/2 antibodies. Shown are representative blots and quantifi cation of 
seven independent experiments. B: 3T3-L1 adipocytes were treated with 2 ng/ml FasL and different concen-
trations of the MEK inhibitor U0126. Shown are representative blots in the upper panel. For the determina-
tion of lipolysis, cells were incubated with FasL for 12 h in the presence (white bars) or absence (black bars) 
of 50 µM U0126, and glycerol release was determined. Results are the means ± SEM of six independent ex-
periments. C: (Left panel) siRNA-treated cells [scrambled (scr, black bars) or target (white bars)] were lysed 
72 h after transfection. Total cell lysates were resolved by LDS-PAGE and immunoblotted with total ERK1/2 
and actin antibodies. Shown are representative blots (upper panel) and densitometry analyses of four inde-
pendent experiments (lower panel). Right panel: Glycerol release was determined 72 h after siRNA-medi-
ated ERK1/2 depletion. Results are the means ± SEM of six independent experiments. D: Cells were 
incubated with or without 5 µM rosiglitazone for 60 h. During the last 6 h or 12 h of such incubation, cells 
were treated with FasL. Left panel: total cell lysates were resolved by LDS-PAGE and immunoblotted with 
anti-phospho-ERK1/2 or anti-ERK1/2 antibodies. Shown are representative blots and quantifi cation of four 
independent experiments. Right panel: glycerol release was determined. Results are the means ± SEM of 
four independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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characterized by an elevated rate of basal lipolysis ( 30 ), 
which might be at least partly mediated by self-production 
of infl ammatory cytokines acting in an autocrine manner, 
possibly as a self-protective cellular mechanism against ex-
cessive cellular over-growth. Third, because insulin is the 
major anti-lipolytic hormone, insulin resistance at the adi-
pocyte level results in increased lipolysis, creating a vicious 
cycle between hypertrophy, infl ammation, lipolysis, and 
insulin resistance. Fas may be a key component of such 
dysregulation: Fas is activated by FasL, which can be pro-
duced by infl ammatory cells infi ltrating adipose tissue in 
obesity. Moreover, expression of Fas is increased in adi-
pose tissue of obese humans and in isolated adipocytes of 
obese and diabetic mice, and intriguingly, its protein ex-
pression correlates with adipocyte size and is therefore in-
creased in hypertrophic adipocytes ( 11 ). 
 In agreement with such notion, we show herein that 
chronic stimulation of the death receptor Fas induced 
well as lipolysis ( Fig. 5C ). These data strongly suggest that 
Ca-mediated activation of CaMKII is a proximal signaling 
response to Fas activation, which is propagated further 
downstream via ERK1/2 to induce basal lipolysis. 
 DISCUSSION 
 In obesity, higher basal lipolysis rate resulting in in-
creased release of NEFAs into the circulation contributes 
to the development of hepatic and total body insulin resis-
tance ( 26 ). Several factors contribute to such increase in 
lipolysis. First, obesity is associated with a persistent low-
grade infl ammation of adipose tissue, as manifested by an 
increased production and secretion of proinfl ammatory 
cytokines such as TNF  and IL-6 ( 27 ). The latter in turn 
can directly stimulate adipocyte lipolysis, even as isolated 
factors ( 21, 28 ,  29 ). Second, hypertrophic adipocytes are 
 Fig.  5. FasL-induced lipolysis is CaMKII dependent. A: 3T3-L1 adipocytes were incubated with 2 ng/ml FasL and different concentrations 
of BAPTA/AM for 12 h. Left panel: the amount of phosphorylated and total ERK1/2 was analyzed in whole-cell lysates by Western blot 
technique. Shown are representative blots and quantifi cation of four independent experiments. Right panel: glycerol release was deter-
mined in adipocytes treated with or without 2 ng/ml FasL and 50 µM BAPTA/AM for 12 h. Results are the means ± SEM of three indepen-
dent experiments. B: 3T3-L1 adipocytes were treated with FasL (2 ng/ml) for the indicated time periods. Lysates were resolved by LDS-PAGE 
and immunoblotted with phospho-CaMKII and actin antibodies. Shown are representative blots and quantifi cation of fi ve independent 
experiments. C: 3T3-L1 adipocytes were incubated with 2 ng/ml FasL and different concentrations of the CaMKII inhibitor KN62 for 12 h. 
Left panel: phosphorylated ERK1/2 was analyzed in whole-cell lysates by Western blot technique. Shown are representative blots and quan-
tifi cation of four independent experiments. Right panel: glycerol release was determined in 3T3-L1 adipocytes treated with or without FasL 
and 10 µM KN62. Results are the means ± SEM of fi ve independent experiments. * P < 0.05, *** P < 0.001. 
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demonstrated to play a role in pheromone biosynthesis in 
insects ( 33 ). 
 Interestingly, the TZD rosiglitazone reduced both Fas-
mediated ERK1/2 phosphorylation and lipolysis. PPAR  
agonists have profound effects on adipocyte metabolism 
and were shown to improve insulin sensitivity in patients 
with type 2 diabetes. Moreover, in a recent paper, treat-
ment with another TZD, pioglitazone, was able to reduce 
whole-body lipolysis in type 2 diabetic patients ( 22 ). We 
previously described a potential role for Fas activation in 
obesity-associated insulin resistance ( 11 ) and show herein 
that Fas activation leads to increased lipolysis. Thus, our 
experiments may point to a role of TZDs in counteracting 
Fas-induced metabolic changes in adipocytes and further 
underscore the importance of ERK-activation for FasL-in-
duced lipolysis. Similarly, TZDs were previously found to 
antagonize the effects of TNF  on adipocytes ( 34 ). 
 We recently showed that treatment of 3T3-L1 adipocytes 
with 2 ng/ml FasL for 12 h reduced protein levels of Akt/
PKB (protein kinase B) ( 19 ). Moreover, a recent publica-
tion reported that deletion of rictor, an essential compo-
nent of the Akt kinase mammalian target of rapamycin 
complex 2 (mTORC2), increases basal lipolysis as well as 
phosphorylation of HSL at Ser563 in adipocytes ( 35 ). 
Hence, it is conceivable that Fas-mediated reduction in Akt 
protein levels contributed to FasL-induced lipolysis, poten-
tially via increased phosphorylation of HSL at serine residue 
563. Moreover, ERK1/2-mediated phosphorylation of HSL 
at Ser600 ( 36 ) might contribute to Fas-induced lipolysis. 
However, such a corresponding anti-phospho-HSLSer600 
antibody is not commercially available and, thus, not avail-
able to us for evaluating a potential role of HSLSer600 
phosphorylation in this study. Besides activation of HSL, we 
cannot exclude the involvement of ATGL to Fas activation-
induced lipolysis, because ATGL protein levels were slight, 
albeit not signifi cantly increased, after FasL treatment. 
 In summary, activation of the Fas receptor alters the me-
tabolism of adipocytes and leads to ERK1/2-mediated li-
polysis, which may be triggered by a Fas-induced increase 
in intracellular calcium levels and hence, autophosphory-
lation of the Ca 2+ /calmodulin-dependent protein kinases 
II. Thus, our fi ndings suggest an important role of the Fas 
receptor in the development of adipose tissue dysfunction 
in the context of obesity.  
 The authors thank Dr. Assaf Rudich from the Department of 
Clinical Biochemistry and the S. Daniel Centre for Health and 
Nutrition, Ben-Gurion University, Beer-Sheva, Israel, for helpful 
discussion. 
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lipolysis in 3T3-L1 adipocytes. Importantly, this effect oc-
curred under conditions that did not induce apoptosis 
( 11 ). Like TNF  , FasL stimulates lipolysis through activa-
tion of the ERK1/2 MAP kinases, because Fas activation 
led to increased phosphorylation of ERK1/2 and pretreat-
ment with the MEK1/2 inhibitor U0126 or siRNA-medi-
ated downregulation of ERK1/2 blocked Fas-induced 
lipolysis. In the case of TNF  , it was proposed that ERK1/2-
dependent downregulation of the lipid droplet coating 
protein perilipin is responsible for the increase in lipolysis 
( 21 ). We also observed a downregulation of perilipin in 
cells treated with FasL for 12 h. However, in contrast to 
TNF  , such effect was not mediated by ERK1/2, because 
FasL-induced decrease in perilipin expression was not pre-
vented by ERK inhibition (see supplementary Fig. VI). 
Moreover, 6 h of FasL incubation did not decrease per-
ilipin protein content (data not shown) but increased FFA 
and glycerol release. All these results suggest that Fas-me-
diated lipolysis is independent of a decrease in perilipin 
expression. 
 Herein, we present evidence for calcium-triggered acti-
vation of ERK in Fas activation-mediated lipolysis. Fas acti-
vation in cells was previously shown to raise intracellular 
free Ca 2+ levels ( 24 ). Similarly, increased intracellular Ca 2+ 
levels induced by endoplasmic reticulum (ER) stress were 
shown to induce lipolysis in adipocytes ERK dependently 
( 31 ). Hence, Fas-induced ERK activation may be mediated 
by ER stress-triggered Ca 2+ release. However, as shown in 
supplementary Fig. VII, FasL stimulation of 3T3-L1 adipo-
cytes did not provoke ER stress. Moreover, the extracellu-
lar Ca 2+ -chelator EDTA blunted Fas-induced ERK activation 
and lipolysis similar to the intracellular chelator BAPTA 
(see supplementary Fig. VIII). Such data suggest that ex-
tracellular Ca 2+ infl ux rather than Ca 2+ release from ER is 
involved in Fas-induced lipolysis. Increased intracellular 
Ca 2+ is bound by the calcium-binding protein calmodulin 
(CaM) forming a complex. The latter then binds to and 
thereby activates CaMKII. Activation of CaMKII by the 
Ca 2+ /CaM complex allows intramolecular autophosphory-
lation at several sites, including Thr286. This generates 
calcium-independent activity that persists after dissocia-
tion of calcium/CaM, allowing transient calcium elevation 
to promote prolonged kinase activation ( 25 ). We found 
that FasL treatment increased phosphorylation at Thr286 
of CaMKII. Moreover, Fas activation-induced lipolysis was 
prevented in the presence of the CaMKII inhibitor as well 
as of the Ca 2+ chelator, BAPTA. Thus, we postulate that Fas 
activation in adipocytes increases intracellular Ca 2+ levels, 
leading to activation of CaMKII, which, in turn, activates 
ERK1/2 and, thus, lipolysis. Accordingly, it was previously 
reported that  trans -10,  cis -12-conjugated linoleic acid-in-
duced ERK1/2 activation in adipocytes is dependent on a 
rise in intracellular free Ca 2+ levels and consecutive activa-
tion of CaMKII ( 32 ). Unfortunately, lipolysis was not ad-
dressed in this study. The data presented herein may 
suggest a novel pathway for lipolysis in adipocytes via CaM-
KII-dependent activation of ERK. Interestingly, such a 
pathway may be very ancient and evolutionarily preserved, 
because CaMKII-mediated release of FFAs was recently 
GALLEY PROOF—JLR_M028035
8 Journal of Lipid Research Volume 54, 2013
  4 .  Girousse ,  A. , and  D.  Langin .  2012 .  Adipocyte lipases and lipid 
droplet-associated proteins: insight from transgenic mouse models. 
 Int. J. Obes. (Lond.) .  36 :  581 – 594 . 
  5 .  Souza ,  S. C. ,  H. J.  Palmer ,  Y. H.  Kang ,  M. T.  Yamamoto ,  K. V.  Muliro , 
 K. E.  Paulson , and  A. S.  Greenberg .  2003 .  TNF-alpha induction 
of lipolysis is mediated through activation of the extracellular sig-
nal related kinase pathway in 3T3-L1 adipocytes.  J. Cell. Biochem. 
 89 :  1077 – 1086 . 
  6 .  Carmen ,  G. Y. , and  S. M.  Victor .  2006 .  Signalling mechanisms regu-
lating lipolysis.  Cell. Signal.  18 :  401 – 408 . 
  7 .  Itoh ,  N. ,  S.  Yonehara ,  A.  Ishii ,  M.  Yonehara ,  S.  Mizushima ,  M. 
 Sameshima ,  A.  Hase ,  Y.  Seto , and  S.  Nagata .  1991 .  The polypeptide 
encoded by the cDNA for human cell surface antigen Fas can mediate 
apoptosis.  Cell .  66 :  233 – 243 . 
  8 .  Suda ,  T. ,  T.  Takahashi ,  P.  Golstein , and  S.  Nagata .  1993 .  Molecular 
cloning and expression of the Fas ligand, a novel member of the 
tumor necrosis factor family.  Cell .  75 :  1169 – 1178 . 
  9 .  Lambert ,  C. ,  A. M.  Landau , and  J.  Desbarats .  2003 .  Fas-beyond 
death: a regenerative role for Fas in the nervous system.  Apoptosis . 
 8 :  551 – 562 . 
 10 .  French ,  L. E. ,  M.  Hahne ,  I.  Viard ,  G.  Radlgruber ,  R.  Zanone ,  K. 
 Becker ,  C.  Muller , and  J.  Tschopp .  1996 .  Fas and Fas ligand in 
embryos and adult mice: ligand expression in several immune-
privileged tissues and coexpression in adult tissues characterized 
by apoptotic cell turnover.  J. Cell Biol.  133 :  335 – 343 . 
 11 .  Wueest ,  S. ,  R. A.  Rapold ,  D. M.  Schumann ,  J. M.  Rytka ,  A. 
 Schildknecht ,  O.  Nov ,  A. V.  Chervonsky ,  A.  Rudich ,  E. J.  Schoenle , 
 M. Y.  Donath ,  et al .  2010 .  Deletion of Fas in adipocytes relieves 
adipose tissue infl ammation and hepatic manifestations of obesity in 
mice.  J. Clin. Invest.  120 :  191 – 202 . 
 12 .  Peter ,  M. E. ,  R. C.  Budd ,  J.  Desbarats ,  S. M.  Hedrick ,  A. O.  Hueber , 
 M. K.  Newell ,  L. B.  Owen ,  R. M.  Pope ,  J.  Tschopp ,  H.  Wajant ,  et al . 
 2007 .  The CD95 receptor: apoptosis revisited.  Cell .  129 :  447 – 450 . 
 13 .  Wajant ,  H. ,  K.  Pfi zenmaier , and  P.  Scheurich .  2003 .  Non-apoptotic 
Fas signaling.  Cytokine Growth Factor Rev.  14 :  53 – 66 . 
 14 .  Abreu-Martin ,  M. T. ,  A.  Vidrich ,  D. H.  Lynch , and  S. R.  Targan . 
 1995 .  Divergent induction of apoptosis and IL-8 secretion in HT-29 
cells in response to TNF-alpha and ligation of Fas antigen.  J. Immunol. 
 155 :  4147 – 4154 . 
 15 .  Choi ,  C. ,  G. Y.  Gillespie ,  N. J.  Van Wagoner , and  E. N.  Benveniste . 
 2002 .  Fas engagement increases expression of interleukin-6 in hu-
man glioma cells.  J. Neurooncol.  56 :  13 – 19 . 
 16 .  O’Brien ,  D. ,  T.  O’Connor ,  F.  Shanahan , and  J.  O’Connell .  2002 . 
 Activation of the p38 MAPK and ERK1/2 pathways is required for 
Fas-induced IL-8 production in colonic epithelial cells.  Ann. N. Y. 
Acad. Sci.  973 :  161 – 165 . 
 17 .  Schaub ,  F. J. ,  D. K.  Han ,  W. C.  Liles ,  L. D.  Adams ,  S. A.  Coats ,  R. K. 
 Ramachandran ,  R. A.  Seifert ,  S. M.  Schwartz , and  D. F.  Bowen-Pope . 
 2000 .  Fas/FADD-mediated activation of a specifi c program of in-
fl ammatory gene expression in vascular smooth muscle cells.  Nat. 
Med.  6 :  790 – 796 . 
 18 .  Sekine ,  C. ,  H.  Yagita ,  T.  Kobata ,  T.  Hasunuma ,  K.  Nishioka , and 
 K.  Okumura .  1996 .  Fas-mediated stimulation induces IL-8 secre-
tion by rheumatoid arthritis synoviocytes independently of CPP32-
mediated apoptosis.  Biochem. Biophys. Res. Commun.  228 :  14 – 20 . 
 19 .  Wueest ,  S. ,  R. A.  Rapold ,  E. J.  Schoenle , and  D.  Konrad .  2010 .  Fas 
activation in adipocytes impairs insulin-stimulated glucose uptake 
by reducing Akt.  FEBS Lett.  584 :  4187 – 4192 . 
 20 .  Rosenstock ,  M. ,  A. S.  Greenberg , and  A.  Rudich .  2001 .  Distinct 
long-term regulation of glycerol and non-esterifi ed fatty acid re-
lease by insulin and TNF-alpha in 3T3-L1 adipocytes.  Diabetologia . 
 44 :  55 – 62 . 
 21 .  Souza ,  S. C. ,  H. J.  Palmer ,  Y. H.  Kang ,  M. T.  Yamamoto ,  K. V.  Muliro , 
 K. E.  Paulson , and  A. S.  Greenberg .  2003 .  TNF-alpha induction of 
lipolysis is mediated through activation of the extracellular signal 
related kinase pathway in 3T3-L1 adipocytes.  J. Cell. Biochem.  89 : 
 1077 – 1086 . 
 22 .  Gastaldelli ,  A. ,  A.  Casolaro ,  D.  Ciociaro ,  S.  Frascerra ,  M.  Nannipieri , 
 E.  Buzzigoli , and  E.  Ferrannini .  2009 .  Decreased whole body li-
polysis as a mechanism of the lipid-lowering effect of pioglitazone 
in type 2 diabetic patients.  Am. J. Physiol. Endocrinol. Metab.  297 : 
 E225 – E230 . 
 23 .  Huang ,  S. H. ,  W. J.  Shen ,  H. L.  Yeo , and  S. M.  Wang .  2004 .  Signal-
ing pathway of magnolol-stimulated lipolysis in sterol ester-loaded 
3T3-L1 preadipocyes.  J. Cell. Biochem.  91 :  1021 – 1029 . 
 24 .  Vacher ,  P. ,  N.  Khadra ,  A. M.  Vacher ,  E.  Charles ,  L.  Bresson-
Bepoldin , and  P.  Legembre .  2011 .  Does calcium contribute to the 
CD95 signaling pathway?  Anticancer Drugs .  22 :  481 – 487 . 
 25 .  Wayman ,  G. A. ,  H.  Tokumitsu ,  M. A.  Davare , and  T. R.  Soderling . 
 2011 .  Analysis of CaM-kinase signaling in cells.  Cell Calcium .  50 : 
 1 – 8 . 
 26 .  Delarue ,  J. , and  C.  Magnan .  2007 .  Free fatty acids and insulin resis-
tance.  Curr. Opin. Clin. Nutr. Metab. Care .  10 :  142 – 148 . 
 27 .  Fantuzzi ,  G.  2005 .  Adipose tissue, adipokines, and infl ammation. 
 J. Allergy Clin. Immunol.  115 :  911 – 919 . 
 28 .  Petersen ,  E. W. ,  A. L.  Carey ,  M.  Sacchetti ,  G. R.  Steinberg ,  S. L. 
 Macaulay ,  M. A.  Febbraio , and  B. K.  Pedersen .  2005 .  Acute IL-6 treat-
ment increases fatty acid turnover in elderly humans in vivo and in tis-
sue culture in vitro.  Am. J. Physiol. Endocrinol. Metab.  288 :  E155 – E162 . 
 29 .  Zhang ,  H. H. ,  M.  Halbleib ,  F.  Ahmad ,  V. C.  Manganiello , and  A. S. 
 Greenberg .  2002 .  Tumor necrosis factor-alpha stimulates lipolysis 
in differentiated human adipocytes through activation of extra-
cellular signal-related kinase and elevation of intracellular cAMP. 
 Diabetes .  51 :  2929 – 2935 . 
 30 .  Wueest ,  S. ,  R. A.  Rapold ,  J. M.  Rytka ,  E. J.  Schoenle , and  D.  Konrad . 
 2009 .  Basal lipolysis, not the degree of insulin resistance, differ-
entiates large from small isolated adipocytes in high-fat fed mice. 
 Diabetologia .  52 :  541 – 546 . 
 31 .  Deng ,  J. ,  S.  Liu ,  L.  Zou ,  C.  Xu ,  B.  Geng , and  G.  Xu .  2012 .  Lipolysis 
response to endoplasmic reticulum stress in adipose cells.  J. Biol. 
Chem.  287 :  6240 – 6249 . 
 32 .  Kennedy ,  A. ,  K.  Martinez ,  S.  Chung ,  K.  LaPoint ,  R.  Hopkins ,  S. F. 
 Schmidt ,  K.  Andersen ,  S.  Mandrup , and  M.  McIntosh .  2010 . 
 Infl ammation and insulin resistance induced by trans-10, cis-12 
conjugated linoleic acid depend on intracellular calcium levels in 
primary cultures of human adipocytes.  J. Lipid Res.  51 :  1906 – 1917 . 
 33 .  Ohnishi ,  A. ,  J. J.  Hull ,  M.  Kaji ,  K.  Hashimoto ,  J. M.  Lee ,  K.  Tsuneizumi , 
 T.  Suzuki ,  N.  Dohmae , and  S.  Matsumoto .  2011 .  Hormone signal-
ing linked to silkmoth sex pheromone biosynthesis involves Ca2+/
calmodulin-dependent protein kinase II-mediated phosphorylation 
of the insect PAT family protein Bombyx mori lipid storage droplet 
protein-1 (BmLsd1).  J. Biol. Chem.  286 :  24101 – 24112 . 
 34 .  Souza ,  S. C. ,  M. T.  Yamamoto ,  M. D.  Franciosa ,  P.  Lien , and  A. S. 
 Greenberg .  1998 .  BRL 49653 blocks the lipolytic actions of tumor 
necrosis factor-alpha: a potential new insulin-sensitizing mecha-
nism for thiazolidinediones.  Diabetes .  47 :  691 – 695 . 
 35 .  Kumar ,  A. ,  J. C.  Lawrence ,  Jr .,  D. Y.  Jung ,  H. J.  Ko ,  S. R.  Keller ,  J. K. 
 Kim ,  M. A.  Magnuson , and  T. E.  Harris .  2010 .  Fat cell-specifi c abla-
tion of rictor in mice impairs insulin-regulated fat cell and whole-
body glucose and lipid metabolism.  Diabetes .  59 :  1397 – 1406 . 
 36 .  Greenberg ,  A. S. ,  W. J.  Shen ,  K.  Muliro ,  S.  Patel ,  S. C.  Souza ,  R. A. 
 Roth , and  F. B.  Kraemer .  2001 .  Stimulation of lipolysis and hor-
mone-sensitive lipase via the extracellular signal-regulated kinase 
pathway.  J. Biol. Chem.  276 :  45456 – 45461 . 
[AQ7]
GALLEY PROOF—JLR_M028035
Fas-mediated lipolysis 9
Author: Read proofs carefully. This is your ONLY opportunity to make changes. NO further alterations will be allowed 
after this point.
Author Queries
 [AQ1]:  What does KC indicate? 
 [AQ2]:  Please clarify “set-up to investigate.” Is “prepared to investigate” meant? 
 [AQ3]:  Please spell out p/s. 
 [AQ4]:  Please spell out BCA. 
 [AQ5]:  Please spell out MEK. 
 [AQ6]:  Please spell out TUNEL and MTT. 
 [AQ7]:  Duplicate reference found. Please check reference 21 comparing with reference 5. Please replace Ref. 21 with a 
new reference if possible. If not, please delete Ref. 21 and renumber all subsequent references and citations in 
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